Yeungnam Univ J Med.  2004 Dec;21(2):198-206.

Phase II Study of Paclitaxel and Cisplatin as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer

• Seo YT
• Kim BS
• Go JY
• Choi DS
• Choi SH
• Kim HJ
• Ahn YM
• Roh YH
• Lee KH

Abstract

BACKGROUND
To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. SUBJECTS AND METHODS: Twenty-five patients were enrolled. The patients received 200 mg/m2 paclitaxel as a 3-hour intravenous infusion and 60 mg/m2 cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. RESULTS: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20% (95% confidence interval, 4%~36%) and the median response duration was 4.5 (range, 2-11) months. The median time to progression was 3.3 (range, 0-14) months. The median overall survival of all patients was 7.4 (range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. CONCLUSION: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.

Keyword

Non-small cell lung cancer; Second-line chemotherapy; Paclitaxel; Cisplatin

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy*
Drug Therapy, Combination
Humans
Infusions, Intravenous
Paclitaxel*
Cisplatin
Paclitaxel